secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001570562-24-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q1 revenue up 42% YoY to $59.3M; on track for non-GAAP profitability in Q4 2024
--------------------------------------------------------------------------------

- Net revenue $59.3M (+42% YoY); gross margin 68.3%; non-GAAP loss from ops $0.9M, narrowing from Q4 2023's $3.7M.
- Reaffirms FY2024 revenue guidance of $255-265M; expects non-GAAP profitability in Q4 2024 and full-year 2025.
- FDA submission for Evolysse dermal fillers within 90 days; expanding into Australia and Spain with Nuceiva.
- Added 700+ new customer accounts; reorder rate ~70%; Evolus Rewards members ~825,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/0001570562-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/eols-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001570562-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer